How good are the company's cost analysis and accounting controls? - Philip Fisher
For most of 2019, the China Trade War and drug pricing concerns clobbered many fundamentally strong stocks. In the thick of these market clouds, a downpour of negative sentiments washed away the market cap of most bioscience equities. As my probability analysis revealed, there are signs of a market upturn in the making. As such, I believe that certain stocks will deliver extremely robust returns going forward.
A prime example of the aforesaid phenomenon is Clovis Oncology (CLVS). As you